Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      A Positive Outlook for Lynch Syndrome-Related Cancers

      May 11, 2019
      By Brielle Benyon
      Article

      While Lynch syndrome may be more common than originally thought, research continues to move forward to improve the outcomes of this patient population.

      As more patients undergo genomic sequencing, researchers are discovering that Lynch syndrome is more common than they originally thought.

      The good news, however, is that vaccines may eventually be a promising cancer prevention for this patient population, according to Steven M. Lipkin, MD, PhD, professor of medicine and genetic medicine and the vice chair for basic and translational research at Weill Cornell Medicine.

      “Lynch syndrome confers and approximately 70% to 80% lifetime risk for developing colorectal cancer, and approximately 50% to 60% lifetimes risk for women to develop cancer of the endometrium,” he said in an interview with OncLive, a sister publication of CURE. “There are also other sites that are involved. These include gastric, ovarian, pancreatic, biliary, renal, bladder cancer, and a few others.”

      While treatment options continue to expand for patients with certain genetic mutations, once it is determined that someone has Lynch syndrome, the first goal is to prevent cancer from developing in the first place. For most patients this means more screening, while others may opt for prophylactic surgeries.

      “The cornerstone for management of Lynch syndrome currently is colonoscopies. Surveillance (with colonoscopies) is an important way to try to detect cancers early,” Lipkin said, noting that most individuals with Lynch syndrome get colonoscopies every 2 years. “We also recommend the use of aspirin, which is a nonsteroidal anti-inflammatory agent (NSAID).”

      Colonoscopies can find colorectal cancer before they occur or in the earliest stages, but there are no proven methods to prevent other types of Lynch syndrome-related malignancies.

      “At the moment, we don’t have very effective ways of preventing some of the cancers [located at] the other sites. So, there are a lot of women who will actually choose, after childbearing, to have surgery, similar to women with the BRCA1 or BRCA2 mutation who have a hysterectomy.”

      If patients do develop cancer, there may be more options available to them, depending on the genomic profile of the tumor.

      Lynch syndrome is caused by a germline mutation in 1 of several DNA mismatch repair (dMMR) genes, which are responsible for correcting any errors that occur during the DNA replication process. With these genes not working properly, there may be a long strand of faulty DNA — a condition called microsatellite instability.

      Tumors that are classified as microsatellite instability-high (MSI-H) tend to respond well to immune checkpoint inhibitors. In fact, in 2017, pembrolizumab (Keytruda) was approved for patients with unresectable or metastatic, MSI-H or dMMR deficient solid tumors. Later, in 2018, nivolumab (Opdivo) plus ipilumumab (Yervoy) was approved for MSI-H or dMMR-deficient metastatic colorectal that progressed on prior therapy.

      Looking ahead, cancer vaccines may be added to the toolbox of preventing Lynch syndrome-related cancers.

      “Lynch syndrome patients not only have high rates of developing cancers, but they also [can] develop tumor mutations that are most immunogenic,” Lipkin said.

      Lipkin mentioned a preclinical study where a neoantigen vaccine was tested in mice with Lynch syndrome. The vaccine, which generated antigen-specific responses, reduced intestinal tumors and improved survival. When given with naproxen, overall survival was improved even more.

      “If you think of the idea of having a cancer vaccine as potentially attractive, Lynch syndrome is probably the paradigm place to start. If this is ever going to work, this would be the syndrome,” he added.

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      a man wearing a suit and tie in front of a green screen with the ONN logo
      Susan Sabo-Wagner, MSN, RN, OCN, NEA-BC in an interview with oncology nursing news
      Cheryl VerStrate on the Pitfalls of Direct-to-Consumer Genetic Tests
      Daly
      Karyn Goodman
      Expert in oncology
      Expert in oncology
      Experts in oncology
      Expert in oncology
      Related Content

      Anatomical image of a pancreas with tumors

      Atebimetinib Combo Shows Survival Signal in First-Line Pancreatic Cancer

      Chris Ryan
      June 22nd 2025
      Article

      The novel MEK inhibitor atebimetinib plus chemotherapy showed early signs of survival benefit in first-line treatment of patients with pancreatic cancer.


      The Vitals

      ctDNA Monitoring is a Piece of the Puzzle in CRC Treatment

      Lindsay Fischer
      October 31st 2023
      Podcast

      Holly Chitwood, DNP, FNP-C, AGACNP-BC, explains how circulating tumor DNA monitoring helps providers screen minimal residual disease in individuals with colorectal cancer.


      Anatomical rendering of the human body with the colon highlighted

      Panitumumab Improves Outcomes in RAS/BRAF Wildtype Colon Cancer

      Tony Berberabe, MPH
      May 22nd 2025
      Article

      Adding panitumumab to neoadjuvant FOLFOX cut recurrence risk and improved survival in locally advanced, RAS/BRAF wild-type colon cancer.


      The Vitals

      Terri Pollack Offers Perspective on 2023 ASCO GI Cancers Symposium

      Lindsay Fischer
      March 1st 2023
      Podcast

      In this episode of "The Vitals," Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, underscores potentially practice-changing data which were presented during the 2023 GI Cancers Symposium.


      pancreatic ductal adenocarcinoma

      Proactive Management of NALIRIFOX-Related Diarrhea Is Crucial in Metastatic PDAC

      Ashley Chan
      April 12th 2025
      Article

      Assessing the signs and symptoms of chemotherapy-induced diarrhea and providing accurate and timely patient education may reduce complications and optimize survival outcomes.


      Graphic reading "FDA APPROVED" resembling a stamp of approval

      Cabozantinib Approved for Unresectable, Advanced/Metastatic epNET and pNET

      Bridget Hoyt
      March 26th 2025
      Article

      The FDA approved cabozantinib for use in patients with previously treated unresectable, locally advanced or metastatic, well-differentiated epNETs or pNETs.

      Related Content

      Anatomical image of a pancreas with tumors

      Atebimetinib Combo Shows Survival Signal in First-Line Pancreatic Cancer

      Chris Ryan
      June 22nd 2025
      Article

      The novel MEK inhibitor atebimetinib plus chemotherapy showed early signs of survival benefit in first-line treatment of patients with pancreatic cancer.


      The Vitals

      ctDNA Monitoring is a Piece of the Puzzle in CRC Treatment

      Lindsay Fischer
      October 31st 2023
      Podcast

      Holly Chitwood, DNP, FNP-C, AGACNP-BC, explains how circulating tumor DNA monitoring helps providers screen minimal residual disease in individuals with colorectal cancer.


      Anatomical rendering of the human body with the colon highlighted

      Panitumumab Improves Outcomes in RAS/BRAF Wildtype Colon Cancer

      Tony Berberabe, MPH
      May 22nd 2025
      Article

      Adding panitumumab to neoadjuvant FOLFOX cut recurrence risk and improved survival in locally advanced, RAS/BRAF wild-type colon cancer.


      The Vitals

      Terri Pollack Offers Perspective on 2023 ASCO GI Cancers Symposium

      Lindsay Fischer
      March 1st 2023
      Podcast

      In this episode of "The Vitals," Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, underscores potentially practice-changing data which were presented during the 2023 GI Cancers Symposium.


      pancreatic ductal adenocarcinoma

      Proactive Management of NALIRIFOX-Related Diarrhea Is Crucial in Metastatic PDAC

      Ashley Chan
      April 12th 2025
      Article

      Assessing the signs and symptoms of chemotherapy-induced diarrhea and providing accurate and timely patient education may reduce complications and optimize survival outcomes.


      Graphic reading "FDA APPROVED" resembling a stamp of approval

      Cabozantinib Approved for Unresectable, Advanced/Metastatic epNET and pNET

      Bridget Hoyt
      March 26th 2025
      Article

      The FDA approved cabozantinib for use in patients with previously treated unresectable, locally advanced or metastatic, well-differentiated epNETs or pNETs.

      Latest Conference Coverage

      Allogenic CAR T-Cell Agent Safe, Active in Heavily Pretreated RCC

      No Survival, Recurrence Benefit With Aspirin in CRC Liver Metastases

      Relacorilant Combo Sustains Ovarian Cancer Benefit Post Platinum Break

      Genomic Changes May Drive Sotorasib KRAS G12C+ Combo Resistance in CRC

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.